Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics names Brett Pletcher executive VP and chief legal officer, effective Aug. 19

Neutral Impact 3 of 5 leadership Written later

Cytokinetics hired Brett Pletcher as Executive Vice President, Chief Legal Officer, effective August 19, 2024, under an offer letter dated August 13, 2024. The filing sets his $560,000 base salary and a 45% target bonus, along with sign-on and initial equity awards, which are routine terms for a senior executive hire.

Key points

  • Start date is August 19, 2024; base salary is $560,000
  • Target bonus is 45% of base salary; signing bonus is $100,000
  • Initial equity awards include RSUs and options each valued at $1,891,620, and PSUs valued at $833,520 at target

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECAug 15, 2024, 4:00 PM ET
Accession number0000950170-24-097556

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 15, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.